BridgeBio Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BridgeBio Pharma 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BBIO

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. 

CEO
Neil Kumar
CEONeil Kumar
Employees
839
Employees839
Headquarters
Palo Alto, California
HeadquartersPalo Alto, California
Founded
2015
Founded2015
Employees
839
Employees839

BBIO Key Statistics

Market cap
17.22B
Market cap17.22B
Price-Earnings ratio
-22.30
Price-Earnings ratio-22.30
Dividend yield
Dividend yield
Average volume
2.00M
Average volume2.00M
High today
$83.54
High today$83.54
Low today
$81.33
Low today$81.33
Open price
$84.62
Open price$84.62
Volume
3.25K
Volume3.25K
52 Week high
$93.42
52 Week high$93.42
52 Week low
$42.09
52 Week low$42.09

Stock Snapshot

As of today, BridgeBio Pharma(BBIO) shares are valued at $81.39. The company's market cap stands at 17.22B, with a P/E ratio of -22.30.

On 2026-07-30, BridgeBio Pharma(BBIO) stock traded between a low of $81.33 and a high of $83.54. Shares are currently priced at $81.39, which is +0.1% above the low and -2.6% below the high.

BridgeBio Pharma(BBIO) shares are trading with a volume of 3.25K, against a daily average of 2M.

In the last year, BridgeBio Pharma(BBIO) shares hit a 52-week high of $93.42 and a 52-week low of $42.09.

In the last year, BridgeBio Pharma(BBIO) shares hit a 52-week high of $93.42 and a 52-week low of $42.09.

BBIO News

Simply Wall St 1d
BridgeBio Stock Still Looks Pricey After FDA Filing Acceptance

BridgeBio Pharma stock has delivered a 149.6% return over the past three years, yet its valuation checks lean expensive and suggest the recent strength may alre...

BridgeBio Stock Still Looks Pricey After FDA Filing Acceptance
Investing.com 6d
H.C. Wainwright reiterates BridgeBio Pharma stock rating on FDA filing - Investing.com

...

H.C. Wainwright reiterates BridgeBio Pharma stock rating on FDA filing - Investing.com

Analyst ratings

91%

of 23 ratings
Buy
91.3%
Hold
8.7%
Sell
0%

People also own

Based on the portfolios of people who own BBIO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.